RNA interference screening identifies a novel role for PCTK1/CDK16 in medulloblastoma with c-Myc amplification. by Cwiek, Paulina et al.
Oncotarget116www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 6, No. 1
RNA interference screening identifies a novel role for PCTK1/
CDK16 in medulloblastoma with c-Myc amplification
Paulina Ćwiek1, Zaira Leni1, Fabiana Salm1, Valeriya Dimitrova1, Beata Styp-
Rekowska2, Gianpaolo Chiriano3, Michael Carroll4, Katrin Höland1, Valentin 
Djonov2, Leonardo Scapozza3, Patrick Guiry4 and Alexandre Arcaro1 
1 Division of Pediatric Hematology/Oncology, Bern University Hospital, Bern, Switzerland
2 Institute of Anatomy, University of Bern, Bern, Switzerland
3 Pharmaceutical Biochemistry, School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, 
Switzerland
4 Centre for Synthesis and Chemical Biology, University College Dublin, Belfield, Dublin, Ireland
Correspondence to: Alexandre Arcaro, email: alexandre.arcaro@dkf.unibe.ch
Keywords: c-Myc, medulloblastoma, PCTK1, RNA interference, synthetic lethality 
Received: August 19, 2014 Accepted: November 06, 2014 Published: November 06, 2014
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original author and source are credited. 
ABSTRACT
Medulloblastoma (MB) is the most common malignant brain tumor in children and 
is associated with a poor outcome. cMYC amplification characterizes a subgroup of MB 
with very poor prognosis. However, there exist so far no targeted therapies for the 
subgroup of MB with cMYC amplification. Here we used kinome-wide RNA interference 
screening to identify novel kinases that may be targeted to inhibit the proliferation 
of c-Myc-overexpressing MB. The RNAi screen identified a set of 5 genes that could 
be targeted to selectively impair the proliferation of c-Myc-overexpressing MB cell 
lines: AKAP12 (A-kinase anchor protein), CSNK1α1 (casein kinase 1, alpha 1), EPHA7 
(EPH receptor A7) and PCTK1 (PCTAIRE protein kinase 1). When using RNAi and a 
pharmacological inhibitor selective for PCTK1, we could show that this kinase plays 
a crucial role in the proliferation of MB cell lines and the activation of the mammalian 
target of rapamycin (mTOR) pathway. In addition, pharmacological PCTK1 inhibition 
reduced the expression levels of c-Myc. Finally, targeting PCTK1 selectively impaired 
the tumor growth of c-Myc-overexpressing MB cells in vivo. Together our data uncover 
a novel and crucial role for PCTK1 in the proliferation and survival of MB characterized 
by cMYC amplification.
INTRODUCTION
Medulloblastoma (MB), a tumor arising in the 
cerebellum or medulla is the most prevalent malignant 
brain tumor in children [1]. Current treatments including 
surgery, craniospinal radiotherapy and chemotherapy 
have improved survival rates, which nowadays are 
approximately 80% [2, 3]. Nevertheless, there are still 
numerous patients with poor prognosis and survivors 
suffer from diminished quality of life caused by the 
aggressive therapy [2]. The current classification 
system for medulloblastoma is based on morphology 
(histopathology), and include variants such as 
desmoplastic/nodular, MBEN (medulloblastoma with 
extensive nodularity), classic medulloblastoma, large 
cell, and anaplastic medulloblastoma [4, 5]. During the 
past few years, transcriptome-based, molecular studies on 
cohorts of MB have depicted this tumor not as a single 
disease, but as a cluster of individual molecular subgroups. 
Four subtypes have been proposed with distinct 
characteristics in terms of gene expression, mutational 
profiles, epidemiology, and prognosis: Wnt, Shh, Group 
3, and Group 4 [3, 6-8]. The most aggressive MB subtype 
(Group 3), that consists of ‘classical’ medulloblastomas 
and partially of the large cells/anaplastic (LCA) tumors 
is associated with amplification in cMyc [4]. Current 
treatments fail to cure two thirds of patients in this 
particular group [8]. Thus, it remains of great interest to 
investigate which role c-Myc plays in the biology of MB. 
c-Myc, a potent and frequently deregulated 
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oncogene in human cancers is known to promote tumor 
formation and metastasis by regulating cell proliferation, 
differentiation, angiogenesis and metabolism. Elevated 
c-Myc expression in tumors can occur through various 
mechanisms such as: amplification, chromosomal 
translocation, single nucleotide polymorphism (SNP) 
or mutation in c-Myc-related pathways [9]. Previous 
reports have shown that c-Myc overexpression in cancers, 
is highly correlated with those genes and pathways, 
which might not be essential in the context of normal 
cells [10]. Additionally, as a transcription factor without 
evident druggable domain and regulating essential 
processes in proliferative tissues, c-Myc itself may 
not be an appropriate drug target [11]. A large body of 
evidence has revealed synthetic lethality as a possible 
therapeutic approach to target cancer cells harbouring 
specific oncogenic drivers, while sparing normal cells 
[12, 13]. This alternative approach appears to be a useful 
tool to identify target molecules that in combination with 
c-Myc oncogenic pathways result in synthetic lethality in 
medulloblastoma. 
RESULTS
High throughput siRNA screen (HTS) discovering 
synthetic lethality in MB
To broadly identify genes that are essential for the 
survival of c-Myc-overexpressing MB cells, we performed 
a high-throughput siRNA screen targeting protein and 
lipid kinases in two clones of medulloblastoma DAOY 
cells: empty-vector-transfected (V11) or transfected with 
a c-Myc overexpressing construct (M2.1) [14] (Fig. 1A). 
Both clones were transfected with a kinome-wide library 
containing 3 distinct siRNAs targeting the same gene. 
Statistical analysis indicated which genes when silenced 
led to decreased viability of c-Myc-overexpressing cells in 
comparison to those without overexpression. The outcome 
of the screen is represented as a z-score of survival fraction 
approximating a normal distribution of all 3 siRNAs for 
each gene (Fig. 1B). In high-throughput approaches, off-
targets represent a significant source of false positive 
Figure 1: High-throughput lipid and protein kinase siRNA screen aimed at identifying drug targets for cMyc-
overexpressing medulloblastoma cells. A. Cell line model used for the screen: DAOY V11 transfected with empty vector and DAOY 
M2.1 over-expressing c-Myc (mRNA and protein level). B. Scatter plot of z-scores from the screen. C. Heat map of the top candidates from 
the screen.
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hits. Thus, to avoid off-target effects, only genes which 
had a z-score<-2 with at least 2 different siRNAs were 
considered and are displayed on the heat map (Fig. 1C). 
Among these genes, 5 hits that fulfill these criteria were 
selected for further validation: AKAP12 (A-kinase anchor 
protein), CSNK1α1 (casein kinase 1, alpha 1), EPHA7 
(EPH receptor A7), and PCTK1 (PCTAIRE protein kinase 
1) (Fig. 1C). AKAP12 is a scaffolding protein in signal 
transduction associated with protein kinases A and C and 
is implicated in several cellular processes: cell migration, 
maintenance of cytoskeletal architecture and cell 
proliferation [15]. Casein kinase 1 is a monomeric serine-
threonine protein kinase involved in a number of cellular 
processes including DNA repair, cell division, nuclear 
localization and membrane transport. CSNK1 isoforms 
have key roles in the developmentally important Wnt and 
Hedgehog (Hh) signaling pathways [16]. EPH receptor A7 
belongs to the ephrin receptor subfamily of the protein-
tyrosine kinase family and is involved in mediating 
developmental events, particularly in the nervous system 
[17]. PCTAIRE protein is a member of CDK family with 
a role in cell cycle and proliferation, vesicle trafficking, 
neurite growth and spermatogenesis [18]. 
Validation of siRNA screen candidates
To validate the results of the screen, all 5 candidate 
genes were silenced with two separate siRNA sequences 
(z-score <-2) in both DAOY clones and subsequently 
tested for viability according to the screen scheme. As 
expected, the cell viability of M2.1 cells was decreased 
after target gene silencing, when compared to V11 cells 
without c-Myc overexpression (Fig. 2A). To confirm 
knockdown efficiency two siRNA sequences were 
assayed for target down-regulation by quantitative RT-
PCR. An analysis of gene expression levels indicated that 
both siRNAs efficiently silenced the corresponding target 
genes (Fig. 2B). To rule out that the c-Myc-depended cell 
viability decrease was limited only to DAOY clones, we 
tested the effect of the knockdown of the 5 gene candidates 
in another MB cell line: UW228 with inducible c-Myc-ER 
activation upon tamoxifen (4-OHT) treatment. Consistent 
with our previous observations, knockdown of the selected 
genes upon c-Myc induction led to sensitization of cells, 
although not to the same extent as in DAOY (Fig. 2C). 
Mentioned difference could be explained by various 
expression levels of PCTK1 in DAOY and UW228 
Figure 2: Validation of the screen. A. siRNA knockdown repeated for the 4 hit candidates with two siRNA sequences in cells used in 
the screen. B. Validation of the siRNA transfection efficiency. Quantitative RT-PCR shows gene downregulation after 24 h of transfection 
with two different siRNA sequences. C. Knockdown of gene candidates in UW228 MycER cells. *p<0.05 when c-Myc basal level cells and 
c-Myc over-expressing cells are compared, error bars represent the SD of the mean of three independent experiments. 
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cells, with lower levels in the last one. Subsequently we 
examined the expression profile of the candidate genes in 
MB cell lines with (DAOY M2.1, D458 and D341) and 
without (DAOY V11, DAOY, UW228, PFSK) c-Myc 
overexpression and healthy cerebellum (CB). Protein 
expression levels differed from each other in the panel 
of MB cells and CB (Fig. 3A). The gene expression 
analysis revealed that most of the candidates were down-
regulated when compared to CB with PCTK1 being an 
exception as it was in the most cases up-regulated (Fig. 
3B). Additionally, an analysis of gene expression in the 
microarray analysis and visualization platform r2 (R2: 
microarray analysis and visualization platform: http://
r2.amc.nl) did not reveal any significant differences 
between molecular subgroups of MB, with EPHA7 as an 
exception (Fig. 3C). 
To assess whether any of the 5 candidate genes 
were potential transcriptional targets of c-Myc, we first 
analyzed DNA microarray data from DAOY clones [19]. 
There were no significant changes in the expression of 
the 5 candidate genes between V11 and M2.1 cells (data 
not shown). We subsequently analyzed Chip data from 
MB cells [20] and found that only EPHA7 is a direct 
transcriptional target of c-Myc. 
Pharmacological inhibition of PCTK1 with a 
newly synthetized inhibitor
Considering the highest degree of cell viability 
decrease upon target gene silencing, we chose to focus 
on PCTK1 in our further investigations. PCTK1 kinase 
is among the most poorly characterized CDK family 
members with no evidence of an implication in cancer. A 
PCTK1 inhibitor (indirubin E804) was synthesized based 
on a structure available in the Drugbank: http://www.
drugbank.ca/drugs/DB07766 (Fig. 4A). By the means of 
Visual Molecular Dynamics (VMD) [21] the analysis of 
the crystallographic structure of PCTK1 kinase domain 
in complex with indirubin-based inhibitor (PDBcode: 
3MTL) revealed that the inhibitor binds to the ATP site by 
interacting with the hinge region via H-bond interactions 
(Fig. 4B). In particular, the following hydrogen-bonds 
were identified: (i) the ligand NH group, belonging to the 
indole-2-one moiety, H-bonded to E241 backbone (3.08 
Å); the carbonyl group of the same moiety interacted via 
H-bond with the NH-amide of L243 backbone (2.88 Å); 
(iii) the NH group, belonging to the indole moiety, also 
formed an H-bond with the carbonyl oxygen of L243 
Figure 3: Expression panel of gene candidates in MB cell lines and patient samples. A. Protein expression of gene candidates 
in healthy cerebellum (CB) and MB cell lines with and without c-Myc over-expression. B. Gene expression of gene candidates in CB and 
MB cell line panel. Expression level was normalized to CB (CB=0). C. r2 microarray analysis of gene expression candidates in molecular 
subgroups of MB. 
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backbone (2.89 Å). Whereas the hydroxybutyloxime 
group is located in a solvent-exposed region, the phenyl 
ring of indole-2-one moiety turned out to be oriented in 
an opposite pocket establishing hydrophobic contacts with 
V224, F240, A192, V179 and F305. Other hydrophobic 
contacts within a maximum distance of 3.90 Å have been 
identified by using LigPlot [22] (Supplementary figure 
S2) particularly between the indole ring of the inhibitor 
and the side chains of residues L171 and L293. Notably, 
focusing the attention on the DFG motif, in contrast with 
the CDK2 structure bound to cyclin A2 and complexed 
with the ATP (Din nad Fout)(PDBcode: 1FIN), [23, 24] 
the D304 and F305 residues are respectively fixed in the 
out and in positions confirming the Indirubin-mediated 
block of PCTAIRE1 in the inactive state conformation 
(supplementary figure S2).
A radiometric protein kinase assay (33PanQinase® 
Activity Assay) was used for measuring the kinase activity 
of the PCTAIRE1/CycY protein kinase. The IC50 of the 
compound was determined to be 53nM ± 9.8nM in vitro, 
suggesting a relatively potent inhibitory activity of the 
inhibitor (Fig. 4C). 
In order to determine the sensitivity of the two 
DAOY clones to the PCTK1 inhibitor dose-dependency 
studies were performed (Fig. 4D). c-Myc overexpressing 
cells (M2.1) were more sensitive to the PCTK1 inhibitor 
than those with basal c-Myc levels. A similar trend was 
shown in cells with endogenous c-Myc overexpression 
(D283, D458, D341) (Fig. 4E, upper panel) and in cells 
with inducible c-Myc – (UW228-Myc-ER treated with 
4-OHT in comparison to un-induced cells) (Fig. 4E, 
lower panel), indicating a broad cytostatic effect of the 
inhibitor in c-Myc overexpressing MB cells. The statistical 
significance was evaluated: (1) between c-Myc basal level 
and c-Myc over-expressing cell lines; or (2) between 
different conditions and control. 
 In order to evaluate the specificity of the inhibitor 
toward PCTK1, we investigated whether silencing of 
PCTK1 could change the impact of the compound on the 
viability of DAOY M2.1 cells. A rescue in the viability 
of PCTK1-knock-down cells, without a comparable effect 
on the scrambled-transfected control cells was observed 
up to a 5 µM concentration of the compound, suggesting 
selectivity of the inhibitor towards PCTK1 (Fig. 4F).
Figure 4: Synthesized PCTK1 inhibitor and its effect on MB cell lines. A. Chemical structure of the PCTK1 inhibitor, indirubin 
E804. B. 3D cartoon of indirubin E804 binding into PCTK1 kinase domain visualized by Visual Molecular Dynamics (VMD) - molecular 
visualization program. The inhibitor’s carbon atoms are in light blue while the hinge-region ones are in orange. The h-bonds are shown 
as black dotted lines. The DFG motif is in magenta while the rest of the protein is in cyan. C. A radiometric kinase assay (33PanQinase® 
Activity Assay) of the PCTAIRE1/CycY protein kinase activity. D. Inhibitor titration in DAOY V11 (grey circles) and M2.1 cells (black 
squares) E. Inhibitor titration in panel of MB cell lines (upper and lower panel). F. Inhibitor titration in DAOY M2.1 cells transfected with 
siRNA against PCTK1 (black triangles) or scrambled siRNA (grey circles). 
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PCTK1 inhibition alters c-Myc expression and 
stability
The observed effect of the inhibitor on c-Myc 
overexpressing cells led us to investigate whether PCTK1 
inhibition has a direct influence on c-Myc protein levels. 
Indeed c-Myc protein expression decreased upon PTCK1 
inhibitor treatment in a dose-dependent manner (Fig. 
5A). In addition, PCTK1 inhibitor treatment impaired 
the phosphorylation of GSK-3α/β (Tyr 279/Tyr 216) in 
DAOY V11 and M2.1 cells (Figure 5B). Interestingly, 
phosphorylation of GSK-3β at Ser9 was significantly 
deceased upon inhibitor treatment, which is an important 
observation relevant for c-Myc degradation. However, 
phosphorylation of GSK-3α at Ser21 remained unchanged. 
Nevertheless, there was no notable difference in the effect 
of the inhibitor on GSK-3 phosphorylation between 
the two cell lines (Fig. 5B, upper panel). Similarly, 
phosphorylation of GSK-3β at Ser9 was decreased upon 
PCTK1 inhibition in two MB cell lines with endogenous 
c-Myc overexpression (D283 and D458) (Fig. 5B, lower 
panel). Additionally, in one of the c-Myc overexpressing 
cells (D458) the phosphorylation levels of GSK-3 at Ser21 
was decreased.
Cell cycle and cell proliferation alteration upon 
PCTK1 inhibitor treatment
As PCTK1 is a member of CDKs and displays peak 
expression and maximal activity during the S-phase of the 
cell cycle [25], we investigated whether depletion of this 
kinase had an impact on cell cycle progression in MB. 
We analysed the stages of the cell cycle in untreated and 
treated populations of MB cells using PI uptake analyzed 
by FACS. We showed that PCTK1 inhibition resulted 
in G2/M arrest in both DAOY clones indicating its 
putative role in cell cycle in MB, independently of c-Myc 
(Fig.5C). However, the effect was abolished at the highest 
concentration of the inhibitor due to elevated cell death. 
Subsequent analysis of the effect of PCTK1 inhibition 
on newly synthesized DNA in replicating cells provided 
a possible elucidation of synthetic lethality identified 
Figure 5: PCTK1 inhibition affects numerous cellular processes in c-Myc hallmarked MB cell lines. A. c-Myc protein 
level upon PCTK1 pharmacological inhibition. B. Analysis of GSK3α/ß protein level upon treatment with PCTK1 inhibitor in MB cell 
lines. C. Cell cycle analysis was performed by PI (Propidium Iodide) DNA content measurement by FACS. G2/M arrest was observed upon 
inhibitor treatment independently of c-Myc status. D. BrdU incorporation measurement demonstrating cell proliferation decrease in dose 
dependent manner. 
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in the RNAi screen. An analysis of BrdU incorporation 
during the S-phase of the cell cycle showed that depletion 
of PCTK1 led to decreased cell proliferation in a dose-
dependent manner in the c-Myc-overexpressing MB cell 
line (Fig. 5D).
PCTK1 inhibition affects the AKT/mTOR 
signaling pathway and induces cell death
To gain further insight into the mechanism of action 
of the compound, we investigated whether inhibition of 
PCTK1 had an influence on survival signalling pathways 
upstream of c-Myc. Among the signaling components 
altered by PCTK1 inhibition in c-Myc-overexpressing 
cells (DAOY M2.1 and D458), we identified p-4E-
BP and p-S6 (Fig. 6A and B). This indicates that the 
inhibitor affects the Akt/mTOR pathway as 4E-BP and 
S6 protein are targets of mTOR, which plays a key role 
in protein translation and cell growth [26]. Interestingly, 
the expression levels of these proteins increased in V11 
cells when treated with high concentration of the PCTK1 
inhibitor (10µM), suggesting the existence of a positive 
feedback loop (Fig. 6A). Phosphorylation of Akt (Ser473) 
was diminished in M2.1 cells, while higher concentrations 
of the PCTK1 inhibitor restored phosphorylation levels in 
DAOY V11 cells. 
There is evidence that mTOR inhibition impairs the 
proliferation and survival of c-Myc-overexpressing cancer 
cells, but this inhibition does not directly involve an effect 
on expression of the c-Myc protein [27]. We could confirm 
this observation in MB cell lines by showing that c-Myc 
sensitizes MB cells to mTOR inhibition with PP242 [28]. 
However, c-Myc protein levels did not change markedly 
upon PP242 treatment (Supplementary figure S3).
To determine whether PCTK1 inhibition also 
induces cell death, we performed a Trypan Blue dye 
exclusion test upon PCTK1 inhibitor treatment. c-Myc 
over-expression sensitized MB cells for PCTK1 inhibition 
as more trypan blue positive cells (non-viable) appeared in 
DAOY M2.1 in comparison to V11, particularly at lower 
concentrations (Fig. 6C). Additionally, Fluorescence 
Activated Cell Sorting (FACS) analysis revealed a 
pronounced accumulation of M2.1 cells with hypodiploid 
DNA content (sub-G1) in a dose-dependent manner; 
whereas only a minor accumulation of sub-G1 population 
was observed in V11 cells (Fig. 6D). 
Figure 6: PCTK1 inhibition alters Akt/mTOR pathway in c-Myc hallmarked MB cell lines. A. Analysis of signaling 
pathway regulators protein level upon treatment with PCTK1 inhibitor in DAOY V11 and M2.1 and B. in D458 cells C. PCTK1 inhibition 
induces cell death in dose dependent manner as shown by trypan blue staining and D. sub-G1 cell accumulation.
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PCTK1 Inhibitor blocks tumour growth in a 
Chicken Chorio-Allantoic membrane (CAM) 
model of c-Myc overexpressing MB
The potential effect of pharmacological PCTK1 
inhibition on tumor growth was examined in vivo using 
the Chorio-Allantoic Membrane (CAM) assay. Inoculation 
of DAOY V11 and M2.1 cells on the CAM resulted in 
the formation of solid tumors within three days (Fig. 
7A). Notably, tumors formed by implantation of DAOY 
M2.1 grew more in comparison to DAOY V11, which 
is consistent with the commonly known phenomenon 
that tumors overexpressing c-Myc are characterized 
by a more aggressive phenotype. Treatment of tumors 
for 4 consecutive days with the PCTK1 inhibitor (10 
µM) significantly impaired tumor growth in c-Myc 
overexpressing tumors, when compared to control (DMSO 
treatment) (V<0) (Fig. 7A, B). Importantly, the inhibitor 
was very well tolerated in chicken embryo without 
noticeable toxicity (data not shown). 
DISCUSSION
There exist so far few validated molecular targets 
for c-Myc-amplified cancers and medulloblastoma in 
particular. Intriguingly, the subgroup of MB characterized 
by activated SHH signalling is perhaps the one in which 
most targets have been described so far. The direct 
targeting of c-Myc in MB has been described by various 
approaches, including RNAi and pharmacological 
approaches [29, 30] [31]. In addition, it has been reported 
that interfering with signalling pathways controlled by 
c-Myc can impair MB cell proliferation [11] [32]. 
Loss-of-function screens have been used to identify 
synthetic lethal interaction partners of various oncogenes, 
including Myc [10]. The present study has identified 
several synthetic lethal interactions between c-Myc and 
protein kinases in MB. The kinases identified in the RNAi 
screen were apparently not direct targets of c-Myc (with 
the exception of EPHA7) and did generally not show any 
selectivity in terms of expression in the four molecular 
subgroups of MB. 
PCTAIRE kinases belong to a highly conserved 
subgroup of cyclin-dependent kinases, which generally 
remain poorly characterized. Vertebrates possess three 
Figure 7: Chick Chorioallantoic Membrane (CAM) tumor growth assay as a model to study PCTK1 inhibition in vivo. 
A. DAOY V11 or M2.1 – derived tumors formed on (CAM) were treated with dimethylsulphoxide (DMSO) (control) or 10 μM of inhibitor. 
B. Quantification of tumor volume before and after treatment is shown. Lines indicate the mean of each group.
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highly similar PCTK isoforms (PCTK1,2,3, also termed 
CDK16,17,18), which are most abundantly expressed 
in post-mitotic cells in brain and testis [24]. The highest 
expression levels of PCTK1 are found in the pyriform 
cortex, hippocampus and cerebellum [33] [34] [35]. The 
selective enrichment of PCTK1 expression in brain may 
reflect its role in MB. A recent report has demonstrated a 
link between PCTK1 and tumorigenesis. PCTAIRE1 was 
shown to play an essential role in the mitosis of tumor cells 
and the tumor suppressor p27 was discovered as a novel 
substrate of PCTK1. An evaluation of PCTK1 expression 
levels in primary tumors showed that its expression was 
significantly elevated in prostate and breast cancer [36]. 
PCTK1 belongs to group of proteins containing 
carboxy-terminal sequence binding PDZ (PSD95-
Discs Large-Zonula Occludens) domains. PDZ domains 
containing proteins are involved in many different cellular 
processes and disturbance of PDZ networks is observed 
in many pathologies, including cancer [37] [38]. A two-
hybrid screen in yeast described new potential interaction 
partners of PCTK1: SNX27, MAGI3 and PTPN3 [39]. 
Other proteins were also reported as substrates of PCTK1, 
including MBP (Myelin Basic Protein) and Histone H1 
[40],[33]. Several studies presented the possible mode of 
activation and function of PCTAIRE-1 in cells. Firstly, 
PCTAIRE is phosphorylated by PKA (Protein Kinase A) 
at four sites in its N-terminal region, with S153 being an 
inactivating site. [41]. CDK5-mediated phosphorylation at 
S95 enhances PCTK1 activity [40]. PCTAIRE kinase 1 is 
activated by cyclin Y (CCNY), a highly conserved single 
cyclin [24, 25].
PCTK1 inhibition in MB resulted in decreased DNA 
synthesis and cell death. Initially, we determined whether 
apoptosis is the process responsible for death of MB cells. 
However, we found no evidence of apoptosis upon PCTK1 
inhibition, which confirms previous reports that PCTK1 
does not play a role in apoptosis [41].
The simplest model accounting for the selective 
effect of the PCTK1 inhibitor on the proliferation of MB 
cell lines over-expressing c-Myc is that this compound 
down-regulates c-Myc expression. Indeed, a previous 
report has documented that RNAi-mediated silencing of 
c-Myc impairs cell proliferation in MB cell lines over-
expressing the oncogene [30]. The observation that PCTK1 
inhibitor treatment impairs GSK-3β phosphorylation on 
Ser9 provides a possible link between PCTK1 and c-Myc 
at the molecular level. Indeed, PCTK1 phosphorylates 
GSK-3-derived peptides in vitro. Phosphorylation of 
GSK-3β at Ser9 decreases its activity, thus inhibition of 
this phosphorylation upon PCTK1 inhibitor treatment 
increases GSK-3β activity leading to degradation of 
c-Myc.
Several recent reports have documented that 
targeting PI3K/mTOR pathway can impair the 
proliferation and survival of MB, including mouse models 
of c-Myc-amplified MB [42] [43]. In neuroblastoma, 
another embryonal tumor, in which amplification of MYC 
family genes is correlated with poor prognosis, targeting 
PI3K/mTOR resulted in down-regulation of MYCN 
expression. Tuberous sclerosis complex (TSC) proteins 
may represent a putative link between PCTK1 and the 
mTOR pathway. Both TSC2 and TSC1 are regulated by 
phosphorylation [44]. TSC1 is phosphorylated at multiple 
sites by cyclin-dependent kinase 1 (CDK1)/cyclin B 
during the G2/M phase of the cell cycle [45].
 Together, our findings indicate that PCTK1 is a new 
molecular target in c-Myc-overexpressing MB and suggest 
a therapeutic option to improve the treatment of high-risk 
MB patients.
MATERIAL AND METHODS
Cell culture and reagents
Medulloblastoma (MB) cells were purchased from 
the American Type Cell Culture Collection. DAOY, D283, 
D328, D458 and DAOY V11 and DAOY M2.1 cells 
were cultured in Improved MEM medium (Invitrogen, 
Carlsbad, CA, USA) supplemented with 1% L-glutamine 
(Invitrogen, Carlsbad, CA, USA), 1% Penicillin/
Streptomycin (Invitrogen Carlsbad, CA, USA), 10% fetal 
calf serum (DAOY, D458, V11, M2.1) and 20% fetal calf 
serum (D238). Antibiotic G418 (Promega, Madison, WI, 
USA) was added in concentration 500µg/ml to DAOY 
clones (V11 and M2.1) for selection. UW228-MycER 
and PFSK cells were cultivated in Dulbecco’s modified 
Eagle’s medium (Sigma-Aldrich, Buchs, Switzerland) 
supplemented with 1% L-glutamine (Invitrogen, Carlsbad, 
CA, USA), 1% Penicillin/Streptomycin (Invitrogen, 
Carlsbad, CA, USA) and 10% fetal calf serum (Invitrogen, 
Carlsbad, CA, USA). 1 μmol/L 4-hydroxytamoxifen 
(4OH-T) (Sigma-Aldrich, Buchs, Switzerland) was added 
to culture medium of UW228-MycER cells to induce Myc 
expression.
High throughput siRNA screen (HTS) design and 
validation
The medulloblastoma DAOY cell line with basal 
level of c-Myc was engineered to stably overexpress 
c-Myc, as described herewith [14]. DAOY clones V11 
and M2.1 were plated in triplicates at 5000 cells per 
well in 96-well plates and transfected with 3 different 
siRNA targeting 719 protein and lipid kinases (Silencer 
Kinase siRNA Library Ambion, Applied Biosystems, 
Foster City, CA, USA) at a final concentration of 
40 nM, using Lipofectamine 2000 according to the 
manufacturer’s instructions (Invitrogen, Carlsbad, CA, 
USA). Additional controls were added to each plate 
of the library: negative control - siCONTROL non-
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targeting siRNA Pool (Dharmacon, Waltham, MA, 
USA) and positive controls: siRNA for PLK1 and 
AllStars Hs Cell Death Control siRNA (Qiagen, Venlo, 
Netherlands). At 48 h following transfection cell viability 
was assessed using MTS ((3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium) assay (Promega, Madison, WI, USA). 
The evaluation of the HTS was utilized by median 
centered Z-scores of the surviving fractions calculation 
as described in Zhang et al [46]. Two distinct siRNA 
sequences targeting each candidate hit kinase were used 
to validate results from the screen (AKAP12: siRNA IDs 
137856 and 137858; CSNK1a1: siRNA IDs 178 and 179; 
EPHA7: siRNA IDs 103321 and 527; PCTK1: siRNAs 
ID 1566 and 1472 (Ambion, Applied Biosystems, Foster 
City, CA, USA). Validation of RNAi gene silencing was 
evaluated 48 h after transfection by western blotting for 
protein expression and by semi-quantitative PCR for gene 
expression.
Western blotting
Protein expression was analyzed by western blotting 
as described in Arcaro et al. [47]. The following antibodies 
were used: cMyc, p-AKT (Ser473), p-4E-BP1 (Thr37/46), 
p-S6 Ribosomal Protein (Ser240/244) (Cell Signaling 
Techology, Danvers, MA, USA), Ephrin receptor A7, 
casein kinase I α, PCTAIRE-1, GSK-3ß, p-GSK-3α/ß (Tyr 
279/Tyr 216) (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA), A kinase (PRKA) anchor protein 12 (Epitomics, 
Burlingame, CA, USA), ß-actin and α-tubulin (Sigma, 
Buchs, Switzerland). Quantification of protein expression 
was performed using TotalLab Quant (TotalLab Limited, 
UK).
Quantitative RT-PCR 
RNA was extracted using RNeasy Mini 
Kit (Qiagen, Venlo, Netherlands) following the 
manufacturer’s instructions. The primers for 
18S (5´-CCTCCAATGGATCCTCGTTA-3´ 
R, 5´-AAACGGCTACCACATCCAAG-3´ F), 
ß-actin (5´-AGCACTCTGTTGGCGTACAG-3´ 
R, 5´-GGACTTCGAGCAAGAGATGG-3´ F), 
AKAP12 (5´-CATGGCTCCTCCGCACTTCTC-3´ 
R, 5´-GTCTCCTTCATTCGCAGGCT-3´ F), 
EPHA7 (5´-AGGTCCGTTCCCTTTGATCT-3´ 
R, 5´-AGAGGCTCTTTGCTGCTGTC-3´ F), 
PCTK1 (5´-GTTTCCCAAAGCCAATCTCA-3´ 
R; 5´-GGAGAGTGACCAGGCTTCAG-3´ F) and 
CSNK1α1 (5´-TGTTGCCTTGTCCTGTTGTC -3´ 
R; 5´-GGATCTTCTGGGACCTAGCC -3´ F) were 
purchased from Microsynth (Balgach, Switzerland). 18S 
and ß-actin genes were used as housekeeping genes. 
cDNA was transcribed using the High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystem, California, 
USA) under the following condition: 25°C for 10min, 
37°C for 120min and 85 °C, 5sec. Quantitative RT-PCR 
with SYBR green detection was performed on a ViiA™ 7 
Real-Time PCR System (Applied Biosystem, California, 
USA) using the following condition: 50°C for 2min, 95°C 
for 10min followed by 40 cycles of: 95 °C for 15sec and 
60°C for 1min; and 95°C for 15sec, 60°C for 1min and 
95 °C for 15sec. Average fold changes were calculated by 
differences in threshold cycles (Ct) between samples.
Trypan Blue dye exclusion test 
After 24h treatment with inhibitor cells re-
suspended in PBS were mixed with 0.1% trypan blue dye 
(Buchs, Switzerland, Sigma) in dilution 1:1. Cells were 
counted using a hemocytometer under a light microscope. 
Viable and nonviable cells were recorded separately, and 
the means of two independent cell counts were pooled 
for analysis. Percentages of living cells compared to the 
control were calculated.
Protein kinase assay
A radiometric protein kinase assay (33PanQinase® 
Activity Assay) was performed by ProQinase Targeting 
Cancer to measure the kinase activity of the PCTAIRE1/
CycY protein kinase. The reaction was executed in 96-
well plate by mixing following reagents: 10ul non-
radioactive ATP solution, 25 μl of assay buffer/ [γ-33P]-
ATP mixture, 5 μl of test sample in 10% DMSO and 10 
μl of enzyme/peptide substrate GSK3(14-27) mixture. 
Protein kinase was expressed in Sf9 insect cells or 
in E.coli as recombinant GST-fusion proteins or His-
tagged proteins was produced from human cDNA. 
The reaction was incubated at 30° C and was stopped 
after 60 minutes with 50 μl of 2 % (v/v) H3PO4, 
plates were aspirated and washed twice with 200 μl 
0.9 % (w/v) NaCl. Incorporation of 33Pi (counting of 
“cpm”) was determined with a microplate scintillation 
counter (Microbeta, Wallac). The residual activity (in 
%) was calculated by using the following formula: 
. IC50 values were calculated in Prism 5.04 using 
mathematical model “Sigmoidal response (variable 
slope)“.
Flow cytometry
Fluorescence activated cell sorting (FACS) was 
employed to assess cell cycle, cell death and proliferation. 
Briefly, to assess cell cycle DAOY V11 and M2.1 cells 
were seeded at 2x105 cells per well in 6-well plates and 
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treated with PCTK1 inhibitor and vehicle (DMSO). After 
24h treatment cells were collected and fixed in ice-cold 
100% ethanol overnight. Cell pellets were re-collected 
and re-suspended in 40µg RNase A RNase A/50µg 
Propidiumiodide (Buchs, Switzerland, Sigma) cocktail in 
dark at 4°C for 30min. Proliferation of DAOY cells were 
assessed by bromodeoxyuridine (BrdU) incorporation 
using FITC BrdU Flow Kit (BD Pharmingen, Allschwil, 
Switzerland) according to the manufacturer´s instruction. 
Flow cytometric determination of DNA content, 
BrdU incorporation and sub-G1 population was conducted 
by LSRII Flow Cytometer (BD Pharmingen, Allschwil, 
Switzerland) and analyzed by FlowJo software (Tree 
Stars, Ashland, OR, USA). 
Chick chorio-allantoic membrane (CAM) assay
Fertilized chicken eggs (gallus gallus) from a local 
hatchery were incubated in a humidified incubator at 37°C. 
On day 3 (D3), a window was opened in the egg shell to 
prevent attachment of the chorio-allantoic membrane to 
the shell, and covered with tape to continue incubation. 
On D7, a silicon ring was placed on the CAM and 5x106 
DAOY V11 and M2.1 cells suspend in 20 μl PBS were 
applied after gentle laceration of the membrane. On D10, 
photos were taken under a Leica M205 FA microscope 
(10 x magnification) supplied with a Canon EOS 5D 
Mark II camera (Canon EOS Utility software) followed 
by tumors treatment for the four constitutive days with 20 
μl of 15uM PCTK1 inhibitor or vehicle (DMSO). On D14, 
post-treatment photos were acquired and tumor volume 
was estimated by  ,where r=  [48].
Chemical synthesis of PCTK1 inhibitor
Synthesis reactions and HPLC chromatograms are 
displayed in supplementary figure S1. Chemical synthesis 
of inhibitor was prepared according to a previously 
reported procedure [49]. Briefly, to a solution of indoxyl 
acetate 2 (5.00 g, 28.5 mmol) in anhydrous methanol 
(70 mL) under nitrogen was added isatin 1 (4.20 g, 28.8 
mmol) and sodium carbonate (6.50 g, 61.3 mmol). After 
30 min of stirring and standing for 24 h, slurry was filtered 
and washed with cold methanol and cold water. Obtained 
indirubin 3 (2.50 g, 9.5 mmol) and hydroxylamine 
hydrochloride (1.7g, 24.7 mmol) were refluxed together 
in pyridine (60 mL) for 1.5 h. Subsequently, mixture was 
poured into a 1M solution of hydrochloric acid (100 mL). 
The red/orange precipitate was filtered off, re-dissolved 
in 1M sodium hydroxide (70 mL) and re-precipitated 
with 1M hydrochloric acid (150 mL). The crude product 
was filtered, dried and recrystallized from ethanol/water 
(7:2) to give the product as bright red/orange crystals 
with spectral data in agreement with previously reported 
literature. In the end, Indirubin-3’-oximine 4 (55.4 mg, 
0.20 mmol) and 4-bromobutane-1,2-diol 5 (40.1 mg, 0.24 
mmol) were dissolved in anhydrous dimethylformamide 
(1.5 mL) . To this was added triethylamine (33 µL, 0.24 
mmol). The reaction was stirred under nitrogen for 4 h 
before the solvent was removed in vacuo to produce 
a crude brown oil which was purified via column 
chromatography to give the product as a red solid (36 mg, 
41 % yield) with spectral data in agreement with previous 
reports [50].
Structural Analysis
The 3D structural analysis was carried out by using 
the visualization program VMD [21] in order to examine 
the crystallographic complex of PCTK1/inhibitor within 
the ATP-binding site of kinase domain. In addition, the 
interactions of this complex have been investigated by 
the means of LigPlot [22] which provided a 2D schematic 
representation of H-bonds, hydrophobic and Van der 
Waals contacts.
Statistical Analysis
All statistics were performed in GraphPad Prism 
software (La Jolla, CA, USA). The statistical significance 
between two groups was assessed with two-way ANOVA 
with Bonferroni´s multiple comparison test and p < 0.05 
was consider significant. 
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